HMMR and ovarian cancer: Other studies have shown that RHAMM upregulation is a prognostic indicator for breast cancer, colorectal cancer, endometrial carcinomas, large cell lung cancer, gastric cancer, pancreatic ductal adenocarcinoma, and ovarian cancer [8–15].